Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of nusinersen in patients with spinal muscular atrophy
2015-001870-16Phase 3Completed
- Sponsor
- Biogen
- Start
- Oct 2015
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Primary endpoint: Number of participants experiencing Adverse Events (AEs) and/or Serious Adverse Events (SAEs). Started Oct 2015; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2015-001870-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001870-16.